| NCT ID | NCT05236465 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Norwegian University of Science and Technology |
| Condition | Chronic Fatigue Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-03-21 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-03-21 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal problem. In recent years, a doubling of the number of patients with a CFS/ME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS/ME. Municipalities have expenses in form of care, rehabilitation and other measures. There is a lack of effective treatment for CFS/ME. Evidence-based knowledge is highly needed. If the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.
Eligibility Criteria
Inclusion Criteria: * CFS/ME diagnosis based on the Canada Consensus Criteria. * At least 50% out of school/work. * Readiness to change (corresponding to the preparation phase in transtheoretical model) * Has given informed consent. Exclusion Criteria: * Assessed by a General Practitioner (GP): * Underlying physical illness or mental disorder that may explain the symptoms. * Suicide risk/previous suicide attempts. * Pregnancy. * Bedridden and in need of continuous care. * Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.
Contact & Investigator
Leif Edward Ottesen Kennair, PhD prof
PRINCIPAL INVESTIGATOR
NTNU, Department of Psychology
Frequently Asked Questions
Who can join the NCT05236465 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Chronic Fatigue Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05236465 currently recruiting?
Yes, NCT05236465 is actively recruiting participants. Contact the research team at kennair@ntnu.no for enrollment information.
Where is the NCT05236465 trial being conducted?
This trial is being conducted at Trondheim, Norway.
Who is sponsoring the NCT05236465 clinical trial?
NCT05236465 is sponsored by Norwegian University of Science and Technology. The principal investigator is Leif Edward Ottesen Kennair, PhD prof at NTNU, Department of Psychology. The trial plans to enroll 100 participants.